This group is mostly dedicated to research on biomarkers and molecular mechanisms underlying the development and progression of malignant neoplasms and it aims to provide translational knowledge to advance the diagnosis, prognosis and prediction of a variety of human cancers.

For this purpose, the team combines both morphological (light and ultrastructural microscopy) and advanced molecular tools including next generations sequencing (NGS), in situ hybridisation and immunohistochemistry; these, integrated with bioinformatics tools such as digital pathology, provide a multidisciplinary approach to cancer research. They also have a special interest, and long and productive research tradition in non-neoplastic conditions, including neurodegenerative diseases including dementias and nephropathology amongst others.

The group of Cancer Molecular Pathology and Vulnerabilities (CAMOPAVUL) has been recognized as a Consolidated Research Group (2021SGR01490) with financial support by the Agency for Management of University and Research Grants (AGAUR) of the Government of Catalonia.

Keywords: Cancer, NGS, molecular pathology, traslational research.

Molecular and Translational Pathology

Research lines

Breast and genitourinary neoplasms

Pedro L. Fernández, M. Carmen  Gómez-Plaza, Eva Castellá, Cristina Carrato

Lymphoid and mesenchymal neoplasms

Gustavo Tapia, José L. Mate, Caterina Fumagalli

Respiratory tract, and head & neck neoplasms

José L. Mate, Alba Hernández, Ariadna Quer

Digestive and hepatobiliary tract neoplasms

Raquel López, Alba Hernández, Laura Hernández, Caterina Fumagalli

Nervous and endocrine systems  neoplasms, and neurodegenerative disorders

Cristina Carrato, Aurelio Ariza, Katrin Beyer

Skin neoplasms

Ariadna Quer, Caterina Fumagalli, Paula Rodriguez

Nefropathology and fetal pathology

Dolores López Álvarez, Paula Rodriguez, Marta Ávila

Molecular pathology

A Muñoz, Carolina Sanz


Pedro L. Fernández

Active projects

Molecular characterization of genomics and phenotypical patterns related to resistance to neoadjuvant therapy in triple negative and Her2 positive breast carcinomas

PI: Pedro L. Fernández  
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: PI19/01371
Start Date: 01/01/2020
End Date: 31/12/2022

Comprehensive molecular and microspectroscopic profiling of breast carcinomas and their resistance to neoadjuvant treatment

PI: Pedro L. Fernández  
Funding agency: La Marató de TV3
Agency code: 567/2019
Start Date: 01/01/2020
End Date: 31/12/2022

Análisis epigenómico integral del linfoma plasmablástico: identificación de características epigenéticas para mejorar el diagnóstico y pronóstico de los pacientes   

PI: José Tomás Navarro 
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: PI19/01588
Start Date: 01/01/2020
End Date: 31/12/2022

Validación de las alteraciones genómicas en el glioblastoma: búsqueda de puntos débiles para intervención terapéutica (VAL-GLIO-THERINT)

PI: Cristina Carrato
Funding agency: Instituto de Salud Carlos III (ISCIII)
Start Date: 01/01/2022
End Date: 31/12/2024

Scientific publications

Felip E, Gutiérrez-Chamorro L, Gómez M, Garcia-Vidal E, Romeo M, Morán T, Layos L, Pérez-Roca L, Riveira-Muñoz E, Clotet B, Fernandez PL, Mesía R, Martínez-Cardús A, Ballana E, Margelí M. Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types. Cancers (Basel). 2022 Jan 27;14(3):641. DOI: 10.3390/cancers14030641. PMID: 35158911; PMCID: PMC8833711.

Fernández PL, Rodriguez P, Margeli M, Sanz C, Muñoz AM, Urbizu A, Quiroga V, Castillo A, Cirauqui B, Teruel I, Castella E, Felip E, Perello C, Pons L, Leon LH. Characterization of Residual TN and HER2 Breast Carcinomas after Neoadjuvant Therapy. Modern Patology. 2022 Mar 1.

Temprana-Salvador J, López-García P, Castellví Vives J, de Haro L, Ballesta E, Rojas Abusleme M, Arrufat M, Marques F, Casas JR, Gallego C, Pons L, Mate JL, Fernández PL, López-Bonet E, Bosch R, Martínez S, Ramón Y Cajal S, Matias-Guiu X. DigiPatICS: Digital Pathology Transformation of the Catalan Health Institute Network of 8 Hospitals-Planification, Implementation, and Preliminary Results. Diagnostics (Basel). 2022 Mar 30;12(4):852. DOI: 10.3390/diagnostics12040852. PMID: 35453900; PMCID: PMC9025604.

Pons L, Hernández-León L, Altaleb A, Ussene E, Iglesias R, Castillo A, Rodríguez-Martínez P, Castella E, Quiroga V, Felip E, Cirauqui B, Margelí M, Fernández PL. Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer. Sci Rep. 2022 May 17;12(1):8176. DOI: 10.1038/s41598-022-11411-5. PMID: 35581229; PMCID: PMC9114341.


IGTP wraps up successful round of La Marató visits to its laboratories

The four visits under the "Visita la recerca" (Visit the research) cycle of the Fundació La Marató de TV3 at the Germans Trias i Pujol Research Institute (IGTP) have drawn to a successful close. More than 50 collaborators have had the opportunity to gain insight into various research projects funded through this charitable initiative.

- Campus Can Ruti

The IGTP presents CARE Translational Program in Cancer Research

CARE, the Translational Program in Cancer Research is the first transversal program promoted by the Germans Trias i Pujol Research Institute (IGTP), and it aims to become a bridge for researchers in the field of cancer who want to bring basic and clinical research together, so that the knowledge and the tools generated in the laboratory can benefit the patient.

+ News


Paula Osorio Recordà

(+34) 93 497 8356 extn. 3059